Abstract：Objective: To analyze the effect of TE and TEC neoadjuvant chemotherapy on CTCs and TSCs in peripheral blood of patients with breast cancer. Methods: 155 cases of patients with breast cancer were selected from January 2015 to June 2016 in our hospital. The patients were divided into control group (77 cases) and observation group (78 cases) according to the random number table method. The patients in control group were treated with TE regimen, the observation group received TEC regimen, the curative effect, adverse reaction, CTCs and TSCs level in the two groups were observed. Results: Compared with the control group, the effective rate of the observation group was 89.7%, the difference was not significant (χ2=0.932, P>0.05), the neutrophils in the observation group were significantly more, the difference was significant (χ2=8.923,P<0.05), but there was no significant difference in gastrointestinal tract reaction, cardiotoxicity, liver function abnormality, thrombocytopenia, alopecia and serum albumin (P>0.05). Compared with the control group, there was no significant difference in CTCs level between the observation group and the control group (χ2=1.293, 1.441, 0.992, P>0.05). There was no significant difference in TSCs between the two groups (χ2=1.903, 1.783, P>0.05), but the level of TSCs in stage Ⅲ was significantly lower than that in stage Ⅲ (χ2= 7.543, P<0.05). Conclusion: The TE and TEC neoadjuvant chemotherapy for breast cancer patients with similar clinical efficacy, TEC program to reduce stage Ⅲ breast cancer patients with peripheral blood TSCs may be better than the TE program.
汪忠淼. TE与TEC新辅助化疗方案对乳腺癌患者外周血CTCs及TSCs的影响[J]. 河北医学, 2017, 23(2): 204-207.
WANG Zhongmiao. TE and TEC Neoadjuvant Chemotherapy on CTCs and TSCs in Peripheral Blood of Patients with Breast Cancer. HeBei Med, 2017, 23(2): 204-207.
[1] 郑莹,吴春晓,张敏璐.乳腺癌在中国的流行状况和疾病特征[J].中国癌症杂志,2013,23(8):561~569. [2] Hormones E,Group B C.Sex hormones and risk of breast cancer in premenopausal women:a collaborative reanalysis of individual participant data from seven prospective studies[J].The Lancet Oncology,2013,14(10):1009~1019. [3] 宋子琰,郑义同,卞宝祥.多西紫杉醇联合替吉奥治疗蒽环类耐药晚期乳腺癌的疗效观察[J].临床肿瘤学杂志,2012,17(2):150~152. [4] Goldhirsch A,Winer E P,Coates A S,et al.Personalizing the treatment of women with early breast cancer:highlights of the St gallen international expert consensus on the primary therapy of early breast cancer 2013[J].Annals of Oncology,2013,24(9):2206~2223. [5] 吕阳,许戈良.肿瘤干细胞与肿瘤转移的关系[J].中国普通外科杂志,2013,22(3):359~362. [6] 姜镕,马春华,朱子龙,等.脑脊液循环肿瘤细胞检测在非小细胞肺癌脑膜转移诊断中的应用[J].中国现代神经疾病杂志,2014,14(8):704~707. [7] 魏东旺,李立花.18F~FDG SPECT/CT联合CA15~3检测对提高乳腺癌术后转移的诊断价值[J].河北医学,2016,22(5):801~803. [8] 江泽飞,邵志敏,徐兵河.NCCN乳腺癌临床实践指南(中国版)[J].北京.第三届NCCN亚洲学术会议.2010:327~328. [9] Tan W,Zhang W,Strasner A,et al.Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling[J].Nature,2011,470(7335):548~553. [10] 章克毅,张仕义,吴智勇,等.可手术三阴乳腺癌对两种新辅助化疗方案的临床近期疗效比较[J].广东医学,2013,34(23):3618~3620.
2017, Vol. 23 
冀公网安备13080202000677号